Cargando…

From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer

Cancerous inhibitor of protein phosphatase 2A (CIP2A), initially reported as a tumor-associated antigen (known as p90), is highly expressed in most solid and hematological tumors. The interaction of CIP2A/p90, protein phosphatase 2A (PP2A), and c-Myc can hinder the function of PP2A toward c-Myc S62...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Beibei, Hu, Huihui, Chen, Xiaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998691/
https://www.ncbi.nlm.nih.gov/pubmed/36911405
http://dx.doi.org/10.3389/fgene.2023.1110656
_version_ 1784903521004421120
author Chen, Beibei
Hu, Huihui
Chen, Xiaobing
author_facet Chen, Beibei
Hu, Huihui
Chen, Xiaobing
author_sort Chen, Beibei
collection PubMed
description Cancerous inhibitor of protein phosphatase 2A (CIP2A), initially reported as a tumor-associated antigen (known as p90), is highly expressed in most solid and hematological tumors. The interaction of CIP2A/p90, protein phosphatase 2A (PP2A), and c-Myc can hinder the function of PP2A toward c-Myc S62 induction, thus stabilizing c-Myc protein, which represents a potential role of CIP2A/p90 in tumorigeneses such as cell proliferation, invasion, and migration, as well as cancer drug resistance. The signaling pathways and regulation networks of CIP2A/p90 are complex and not yet fully understood. Many previous studies have also demonstrated that CIP2A/p90 can be used as a potential therapeutic cancer target. In addition, the autoantibody against CIP2A/p90 in sera may be used as a promising biomarker in the diagnosis of certain types of cancer. In this Review, we focus on recent advances relating to CIP2A/p90 and their implications for future research.
format Online
Article
Text
id pubmed-9998691
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99986912023-03-11 From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer Chen, Beibei Hu, Huihui Chen, Xiaobing Front Genet Genetics Cancerous inhibitor of protein phosphatase 2A (CIP2A), initially reported as a tumor-associated antigen (known as p90), is highly expressed in most solid and hematological tumors. The interaction of CIP2A/p90, protein phosphatase 2A (PP2A), and c-Myc can hinder the function of PP2A toward c-Myc S62 induction, thus stabilizing c-Myc protein, which represents a potential role of CIP2A/p90 in tumorigeneses such as cell proliferation, invasion, and migration, as well as cancer drug resistance. The signaling pathways and regulation networks of CIP2A/p90 are complex and not yet fully understood. Many previous studies have also demonstrated that CIP2A/p90 can be used as a potential therapeutic cancer target. In addition, the autoantibody against CIP2A/p90 in sera may be used as a promising biomarker in the diagnosis of certain types of cancer. In this Review, we focus on recent advances relating to CIP2A/p90 and their implications for future research. Frontiers Media S.A. 2023-02-24 /pmc/articles/PMC9998691/ /pubmed/36911405 http://dx.doi.org/10.3389/fgene.2023.1110656 Text en Copyright © 2023 Chen, Hu and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Chen, Beibei
Hu, Huihui
Chen, Xiaobing
From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer
title From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer
title_full From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer
title_fullStr From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer
title_full_unstemmed From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer
title_short From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer
title_sort from basic science to clinical practice: the role of cancerous inhibitor of protein phosphatase 2a (cip2a)/p90 in cancer
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998691/
https://www.ncbi.nlm.nih.gov/pubmed/36911405
http://dx.doi.org/10.3389/fgene.2023.1110656
work_keys_str_mv AT chenbeibei frombasicsciencetoclinicalpracticetheroleofcancerousinhibitorofproteinphosphatase2acip2ap90incancer
AT huhuihui frombasicsciencetoclinicalpracticetheroleofcancerousinhibitorofproteinphosphatase2acip2ap90incancer
AT chenxiaobing frombasicsciencetoclinicalpracticetheroleofcancerousinhibitorofproteinphosphatase2acip2ap90incancer